Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSPORT: CT-P13 SC Induction in IBD
NCT06274294Phase 3Recruiting
- Sponsor
- CMC Ambroise Paré
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Crohn's disease, ulcerative colitis (UC), sponsored by CMC Ambroise Paré. Started Jul 2024; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06274294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274294.